profit from every $100 of sales.
$0$100
COMPASS Pathways
$9.01-1.21% today
+70.3% in 1 year
1-year low $4.941-year high $15.19
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What COMPASS Pathways sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$288 million of profit last year.
SalesProfit
COMPASS Pathways vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| COMPASS Pathways | No profit yet | ||
 Tenet Healthcare | 16.2× · Fair price | ||
 Solventum | 9.7× · Cheap | ||
 Encompass Health | 24.4× · Fair price | ||
 Fresenius Medical Care AG & Co. KGaA | 10.6× · Cheap |
AI analysis
An AI analyst reads COMPASS Pathways's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -96 | -124 | -157 | -175 | |
| -91 | -115 | -149 | -286 | |
| -92 | -118 | -155 | -288 | |
| -2.16 | -2.32 | -2.30 | -3.08 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 197 | 276 | 214 | 210 |
| Cash | 143 | 220 | 165 | 150 |
| Total debt | 2 | 33 | 32 | 35 |
| Total liabilities | 16 | 50 | 59 | 263 |
| 181 | 226 | 155 | -53 | |
| 42 | 67 | 67 | 94 | |
| -39.3% | -35.3% | -63.0% | – | |
| -50.5% | -52.5% | -100.3% | 544.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -105 | -97 | -119 | -157 | |
| 1 | 0 | – | – | |
| -106 | -97 | -119 | -157 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 13 | 17 | 20 | 14 |
Valuation
- –
- –
- –
- 3.5×
- –
- –
- –
- -12.3%
- -22.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -44.0%
- 139.6%
- -151.0%
- -33.7%
- -45.6%
- –
Growth
- –
- –
- −31.9%
- –
- +23.7%
Financial health
- 1.5×
- 0.01
- 0.5%
- -35.5×
- 3.32
- 3.32
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 964
Bottom 19%of 898
Bottom 7%of 991
What analysts expect
- Average price target
- $17.86
- Range
- $15.00 – $22.00
- 6 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.30 | -0.45 | +33.3% |
| Mar 24, 2026 | -0.59 | -0.41 | −43.9% |
| Nov 4, 2025 | -0.38 | -0.40 | +5.0% |
| Jul 31, 2025 | -0.38 | -0.37 | −2.7% |
| May 8, 2025 | -0.44 | -0.47 | +6.4% |
| Feb 27, 2025 | -0.63 | -0.62 | −1.6% |
| Oct 31, 2024 | -0.56 | -0.60 | +6.7% |
| Aug 1, 2024 | -0.56 | -0.53 | −5.7% |
News
Coinbase Jumps 6% on Compass Point Upgrade Ahead of Senate CLARITY Act Vote; Strategy Climbs 3%, MARA SlipsYahoo Finance · Sep 14, 2026How the private-listing war between Zillow and Compass could cost home buyers and sellersMarketWatch · Aug 28, 2026Outreach Recognized as a Top Partner Program in the World with Ecosystem Compass AwardYahoo Finance · Aug 27, 2026The newest story we have is from Sep 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
42No pass
Philip Fisher
39No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
39No pass
Terry Smith
34No pass
Questions about COMPASS Pathways
Is COMPASS Pathways a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the COMPASS Pathways AI analysis
What does COMPASS Pathways do?
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It is in Medical - Care Facilities.
Does COMPASS Pathways pay a dividend?
No. COMPASS Pathways does not pay a dividend at the moment.
Is COMPASS Pathways stock halal?
Yes. COMPASS Pathways passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has COMPASS Pathways stock done over the past year?
Up 70.3% over the past twelve months, to $9.01. It traded between $4.94 and $15.19 and is 40.7% below its high.
Who are COMPASS Pathways's competitors?
The largest listed companies in the same industry are Tenet Healthcare, Solventum, Encompass Health and Fresenius Medical Care AG & Co. KGaA. The peers table on this page compares their profit, growth and price with COMPASS Pathways's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.